call
today
development
financial
statements
expenses
using
date
revenue
filed
data
presented
loss
receive
software
approval
equivalents
trial
trials
patients
phase
clinical
treatment
studies
hardware
evening
study
cloud
afternoon
tonight
use
available
differ
information
potential
operator
regulatory
solution
therapy
treated
collaboration
filing
disease
update
patient
conference
ended
license
marketable
physicians
liver
efficacy
report
received
approved
partner
candidate
released
cancer
users
enroll
cohort
dosing
total
actual
research
design
milestones
population
published
adoption
deferred
security
endpoint
pivotal
user
preclinical
currently
multiple
application
bookings
enrolled
enrolling
ecosystem
dose
inhibitors
additional
may
candidates
apps
server
file
decision
recognized
obligation
duration
enterprise
commercialization
randomized
current
secure
accounts
securities
installed
unmet
doses
cell
servers
thank
primary
joining
deals
version
therapeutic
organizations
milestone
endpoints
review
pipeline
assets
validation
mutation
analog
risks
platform
common
devices
believe
release
decrease
public
clinic
providers
subscription
royalties
investigators
workloads
revenues
initiate
drug
conducted
submitted
cohorts
inhibitor
dram
based
storage
attach
compute
updates
number
agreement
advanced
mobile
computing
submission
firewall
tolerability
designed
per
discuss
webcast
device
wafer
milligrams
interest
compared
meeting
arr
tumors
registration
receptor
cause
representing
foundry
samples
networking
companies
provide
materially
fab
architectures
fibrosis
time
generation
services
documents
partners
loan
requirements
features
indications
bank
cells
required
diseases
scientific
findings
tolerated
